BIOAGE LABS INC (BIOA)
US09077V1008
Taking everything into account, BIOA scores 2 out of 10 in our fundamental rating. BIOA was compared to 193 industry peers in the Pharmaceuticals industry. While BIOA seems to be doing ok healthwise, there are quite some concerns on its profitability. BIOA has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BIOA has reported negative net income.
1.2 Ratios
BIOA's Return On Assets of -18.93% is fine compared to the rest of the industry. BIOA outperforms 64.92% of its industry peers.
With a decent Return On Equity value of -20.35%, BIOA is doing good in the industry, outperforming 72.25% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.93% | ||
| ROE | -20.35% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BIOA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for BIOA remains at a similar level compared to 1 year ago.
The debt/assets ratio for BIOA is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 4.40 indicates that BIOA is not in any danger for bankruptcy at the moment.
The Altman-Z score of BIOA (4.40) is better than 79.58% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that BIOA is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.01, BIOA is in line with its industry, outperforming 56.02% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 4.4 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 17.63 indicates that BIOA has no problem at all paying its short term obligations.
The Current ratio of BIOA (17.63) is better than 90.05% of its industry peers.
A Quick Ratio of 17.63 indicates that BIOA has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 17.63, BIOA belongs to the best of the industry, outperforming 90.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 17.63 | ||
| Quick Ratio | 17.63 |
3. Growth
3.1 Past
BIOA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -60.75%.
EPS 1Y (TTM)-60.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
The Earnings Per Share is expected to decrease by -22.09% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-88.32%
EPS Next 2Y-27.65%
EPS Next 3Y-22.09%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
BIOA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BIOA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BIOA's earnings are expected to decrease with -22.09% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.65%
EPS Next 3Y-22.09%
5. Dividend
5.1 Amount
BIOA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOAGE LABS INC
NASDAQ:BIOA (12/20/2024, 12:53:00 PM)
6.12
+0.95 (+18.38%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners57.35%
Inst Owner ChangeN/A
Ins Owners6.35%
Ins Owner Change0%
Market Cap219.40M
Analysts86.67
Price Target43.18 (605.56%)
Short Float %7.28%
Short Ratio3.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)-5.06%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-18.55%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.7 | ||
| P/tB | 0.7 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.87
EYN/A
EPS(NY)-3.05
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS8.75
TBVpS8.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -18.93% | ||
| ROE | -20.35% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 17.63 | ||
| Quick Ratio | 17.63 | ||
| Altman-Z | 4.4 |
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-60.75%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-88.32%
EPS Next 2Y-27.65%
EPS Next 3Y-22.09%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-21.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-62.26%
EBIT Next 3Y-45.06%
EBIT Next 5YN/A
FCF growth 1Y-3.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.26%
OCF growth 3YN/A
OCF growth 5YN/A